Mustafa Özgüroğlu - Publications, H-index & Citations

Mustafa Özgüroğlu

istanbul university - cerrahpasa

61H指数

548论文数

4.2W被引数

收录论文 100

发表时间

Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study 在PROpel III期研究中，接受奥拉帕利联合阿比特龙治疗或安慰剂联合阿比特龙治疗转移性去势抵抗性前列腺癌患者的患者报告结局。

European Urology Oncology

IF9.3

2025-11-17

OAAI

Andrew J. Armstrong; Fred Saad; Mototsugu Oya; Karina Vianna; Mustafa Özgüroğlu; Craig Gedye; Gary L. Buchschacher; Ji Youl Lee; Urban Emmenegger; Jiří Navrátil; Juan Antonio Virizuela; Anibal Salazar; Denis Maillet; Hiroji Uemura; Christian Hosius; David McGuinness; Arnold Degboe; Noel Clarke

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial Niraparib和abiraterone acetate联合prednisone治疗HRR缺陷型转移性去势敏感前列腺癌：一项随机III期试验

Nature Medicine

IF50

2025-10-07

OAAI

Gerhardt Attard; Neeraj Agarwal; Julie N. Graff; Shahneen Sandhu; Eleni Efstathiou; Mustafa Özgüroğlu; Andrea J. Pereira de Santana Gomes; Karina Vianna; Hong Luo; Geoffrey T. Gotto; Heather H. Cheng; Won Kim; Carly R. Varela; Daneen Schaeffer; Kassie Kramer; Susan Li; Benoit Baron; Fei Shen; Suneel D. Mundle; Sharon A. McCarthy; David Olmos; Kim N. Chi; Dana E. Rathkopf

Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: outcomes in age, sex, and platinum subgroups from the phase 3 CASPIAN study 度伐利尤单抗联合铂类-依托泊苷治疗广泛期小细胞肺癌：CASPIAN III期研究中不同年龄、性别和铂类亚组的结果

Clinical Lung Cancer

IF3.3

2025-08-05

OAAI

Niels Reinmuth; Jonathan W. Goldman; Yuanbin Chen; Katsuyuki Hotta; Dmytro Trukhin; Galina Statsenko; Maximilian Hochmair; Mustafa Özgüroğlu; Jun Ho Ji; Marina Chiara Garassino; Artem Poltoratskiy; Francesco Verderame; Libor Havel; Igor Bondarenko; György Losonczy; Nikolay Conev; Shannon Kummer; Helen Mann; Priti Chugh; Tapashi Dalvi; Luis Paz-Ares

The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium 吸烟对纳武利尤单抗治疗肾细胞癌结局的影响：土耳其肿瘤学组肾癌联盟的真实世界数据

ONCOLOGIST

IF4.2

2025-07-01

PREAI

Camoz, Elif Sertesen; Bolek, Hatice; Kuzu, Omer Faruk; Sim, Saadet; Karakas, Hilal; Sekmek, Serhat; Guliyev, Murad; Akkus, Aysun Fatma; Isik, Selver; Tural, Deniz; Arslan, Cagatay; Goksu, Sema Sezgin; Sever, Ozlem Nuray; Karadurmus, Nuri; Karacin, Cengiz; Ozguroglu, Mustafa; Sendur, Mehmet Ali Nahit; Yekeduz, Emre; Urun, Yuksel

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study☆帕博利珠单抗联合恩扎卢胺和雄激素剥夺疗法与安慰剂联合恩扎卢胺和雄激素剥夺疗法治疗转移性激素敏感性前列腺癌：随机、双盲、III期KEYNOTE-991研究☆

Annals of Oncology

IF65.4

2025-05-16

PREAI

C. Gratzke; M. Özgüroğlu; A. Peer; M.A.N. Sendur; M. Retz; J.C. Goh; W. Loidl; G. Jayram; S.-S. Byun; C. Kwak; M. Kwiatkowski; R. Manneh Kopp; J.C.V. Limón; J.F.E. Penagos; U. De Giorgi; K.M. da Trindade; C. Niu; Y. Liu; C.H. Poehlein; J.M. Piulats

Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study 在CASPIAN III期研究中，广泛期小细胞肺癌患者自报的不良事件

FUTURE ONCOLOGY

IF2.6

2025-05-07

OAAI

Ozguroglu, Mustafa; Goldman, Jonathan W.; Chen, Yuanbin; Garassino, Marina Chiara; Medic, Nenad; Mann, Helen; Chugh, Priti; Dalvi, Tapashi; Paz-Ares, Luis

Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium 在转移性肾细胞癌中 navigat ing二线疗法：免疫检查点抑制剂与酪氨酸激酶抑制剂的比较分析：土耳其肿瘤学组肾癌联盟的研究

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2025-04-24

OAAI

Musa Barış Aykan; Hatice Bölek; Emre Yekedüz; Elif Sertesen; Deniz Tural; Cengiz Karaçin; Mehmet Ali Nahit Şendur; Gökhan Uçar; Çağatay Arslan; Selver Işık; Saadet Sim; Özlem Nuray Sever; Bekir Hacıoğlu; Sema Sezgin Göksu; Mustafa Özgüroğlu; Nuri Karadurmuş; Yüksel Ürün

Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1 Cemiplimab单药治疗PD-L1表达≥50%的晚期NSCLC患者的一线治疗：EMPOWER-Lung 1研究五年结局

Journal of Thoracic Oncology

IF20.8

2025-03-19

OAAI

Saadettin Kilickap; Ana Baramidze; Ahmet Sezer; Mustafa Özgüroğlu; Mahmut Gumus; Igor Bondarenko; Miranda Gogishvili; Marina Nechaeva; Michael Schenker; Irfan Cicin; Ho Gwo Fuang; Yaroslav Kulyaba; Kasimova Zyuhal; Roxana-Ioana Scheusan; Marina Chiara Garassino; Yuntong Li; Cong Zhu; Manika Kaul; Javier Perez; Frank Seebach; Heather Magnan

Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors

SCIENTIFIC REPORTS

IF3.9

2025-02-21

OAAI

Sen, Gulin Alkan; Oztas, Nihan Senturk; Degerli, Ezgi; Safarov, Shamkhal; Guliyev, Murad; Bedir, Sahin; Can, Gunay; Turna, Hande; Ozguroglu, Mustafa

Osimertinib after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC): Post-progression outcomes from the phase III LAURA study 奥希替尼在局部晚期不可切除（UR）III期表皮生长因子受体突变（EGFRm）非小细胞肺癌（NSCLC）患者（pts）经根治性化疗放疗（CRT）后的应用：来自III期LAURA研究的进展后结局

ANNALS OF ONCOLOGY

IF65.4

2024-12-01

PREAI

Ozguroglu, M.; Ahn, M-J.; Dong, X.; Yang, J. C-H.; Oizumi, S.; Goto, K.; Cobo Dols, M.; Kim, S-W.; Hsia, T-C.; Chindaprasirt, J.; Fujiki, F. K.; Valdiviezo, N.; Poole, L.; Evans, A. L.; Armenteros Monterroso, E.; Lu, S.

Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial 奥拉帕尼联合阿比曲酮治疗转移性去势抵抗性前列腺癌患者的耐受性: 来自PROpel 3期试验的进一步结果

EUROPEAN UROLOGY ONCOLOGY

IF9.3

2024-12-01

OAAI

Saad, Fred; Armstrong, Andrew J.; Oya, Mototsugu; Vianna, Karina; Ozguroglu, Mustafa; Gedye, Craig; Buchschacher Jr, Gary L.; Lee, Ji Youl; Emmenegger, Urban; Navratil, Jiri; Virizuela, Juan Antonio; Salazar, Anibal; Maillet, Denis; Uemura, Hiroji; Kim, Jeri; Oscroft, Emma; Barker, Laura; Degboe, Arnold; Clarke, Noel W.

Outcomes of patients (pts) with unfavourable, nonsquamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study CUPISCO全球开放标签II期研究中，接受诱导化疗（CTX）后进展的预后不良、非鳞癌来源不明肿瘤（CUP）患者的结局

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Bochtler, T.; Kraemer, A.; Pauli, C.; Duran-Pacheco, G.; Arslan, C.; Bigot, F.; Chalabi, N.; Cook, N.; Italiano, A.; Losa, F.; Menezes, J.; Ma, N.; Ozguroglu, M.; Pazo Cid, R. A.; Ross, J. S.; Shiu, K-K.; Arni, P.; Moch, H.; Mileshkin, L.

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC III期EGFR突变的NSCLC放化疗后的奥希替尼

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2024-08-15

PREAI

Lu, Shun; Kato, Terufumi; Dong, Xiaorong; Ahn, Myung-Ju; Quang, Le-Van; Soparattanapaisarn, Nopadol; Inoue, Takako; Wang, Chih-Liang; Huang, Meijuan; Yang, James Chih-Hsin; Cobo, Manuel; Ozguroglu, Mustafa; Casarini, Ignacio; Khiem, Dang-Van; Sriuranpong, Virote; Cronemberger, Eduardo; Takahashi, Toshiaki; Runglodvatana, Yotsawaj; Chen, Ming; Huang, Xiangning; Grainger, Ellie; Ghiorghiu, Dana; van der Gronde, Toon; Ramalingam, Suresh S.

Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer

JCO GLOBAL ONCOLOGY

IF3

2024-08-01

OAAI

Bolek, Hatice; Arslan, Cagatay; Basaran, Mert; Cicin, Irfan; Ozguroglu, Mustafa; Tural, Deniz; Urun, Yuksel

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

LANCET

IF88.5

2024-08-01

PREAI

Kraemer, Alwin; Bochtler, Tilmann; Pauli, Chantal; Shiu, Kai-Keen; Cook, Natalie; de Menezes, Juliana Janoski; Pazo-Cid, Roberto A.; Losa, Ferran; Robbrecht, Debbie G. J.; Tomasek, Jiri; Arslan, Cagatay; Ozguroglu, Mustafa; Stahl, Michael; Bigot, Frederic; Kim, Sun Young; Naito, Yoichi; Italiano, Antoine; Chalabi, Nassera; Duran-Pacheco, Gonzalo; Michaud, Chantal; Scarato, Jeremy; Thomas, Marlene; Ross, Jeffrey S.; Moch, Holger; Mileshkin, Linda

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC 不可切除的III期NSCLC同步放化疗后Durvalumab的症状性肺炎

JTO CLINICAL AND RESEARCH REPORTS

IF3.5

2024-03-01

OAAI

Vansteenkiste, Johan F.; Naidoo, Jarushka; Faivre-Finn, Corinne; Ozguroglu, Mustafa; Villegas, Augusto; Daniel, Davey; Murakami, Shuji; Hui, Rina; Lee, Ki Hyeong; Cho, Byoung Chul; Kubota, Kaoru; Broadhurst, Helen; Wadsworth, Catherine; Newton, Michael; Thiyagarajah, Piruntha; Antonia, Scott J.

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial Erdafitinib与pembrolizumab在患有选择性FGFR改变的晚期或转移性尿路上皮癌的预治疗患者中的比较: THOR III期随机试验的队列2

ANNALS OF ONCOLOGY

IF65.4

2024-01-01

PREAI

Siefker-Radtke, A. O.; Matsubara, N.; Park, S. H.; Huddart, R. A.; Burgess, E. F.; Ozguroglu, M.; Valderrama, B. P.; Laguerre, B.; Basso, U.; Triantos, S.; Akapame, S.; Kean, Y.; Deprince, K.; Mukhopadhyay, S.; Loriot, Y.

Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study 阿帕鲁胺治疗的前列腺特异性抗原 (PSA) 下降与转移性前列腺癌患者的生存期延长和预后改善有关: TITAN研究的简明语言总结

FUTURE ONCOLOGY

IF2.6

2023-12-21

OAAI

Chowdhury, Simon; Bjartell, Anders; Agarwal, Neeraj; Chung, Byung H.; Given, Robert W.; Gomes, Andrea J. Pereira de Santana; Merseburger, Axel S.; Ozguroglu, Mustafa; Soto, Alvaro Juarez; Uemura, Hirotsugu; Ye, Ding-Wei; Brookman-May, Sabine D.; Londhe, Anil; Bhaumik, Amitabha; Mundle, Suneel D.; Larsen, Julie S.; McCarthy, Sharon A.; Chi, Kim N.

Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Mileshkin, L.; Bochtler, T.; Pauli, C.; Duran-Pacheco, G.; Arslan, C.; Bigot, F.; Chalabi, N.; Cook, N.; Italiano, A.; Losa, F.; Menezes, J.; Michaud, C.; Ozguroglu, M.; Cid, R. A. Pazo; Ross, J. S.; Shiu, K. K.; Stahl, M.; Thomas, M.; Moch, H.; Kraemer, A.

Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Siefker-Radtke, A. O.; Matsubara, N.; Park, S. H.; Huddart, R. A.; Burgess, E. F.; Ozguroglu, M.; Perez Valderrama, B.; Triantos, S.; Akapame, S.; Kean, Y.; Deprince, K.; Mukhopadhyay, S.; Loriot, Y.

研究方向